{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:14:06Z","timestamp":1790738046212,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Severe malaria caused by <jats:italic>Plasmodium falciparum<\/jats:italic> leads to most malaria-related deaths globally. Decoquinate (DQ) displays strong activity against multistage infection by <jats:italic>Plasmodium<\/jats:italic> parasites. However, the development of DQ as an oral dosage form for the treatment of malaria at the blood stage has not been successful. In this study, liposome formulations of DQ were created for intravenous (IV) injection to suppress <jats:italic>Plasmodium berghei<\/jats:italic>, a parasite that causes severe malaria in mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>DQ liposomes were prepared by conventional ethanol injection method with slight modifications and encapsulation efficiency evaluated by the well-established centrifugation method. Potency of the DQ liposomes against <jats:italic>P. falciparum<\/jats:italic> was assessed in vitro using freshly isolated human red blood cells. The efficacy of the DQ liposomes was examined in the mouse model of severe malaria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The DQ liposomes were around 150\u00a0nm in size and had the encapsulation efficiency rates &gt;\u200995%. The freshly prepared and lyophilized liposomes were stable after storage at \u2212\u200920\u00a0\u00b0C for 6\u00a0months. The liposomes were shown to have excellent activity against <jats:italic>P. falciparum<\/jats:italic> in vitro with DQ IC<jats:sub>50<\/jats:sub> 0.91\u2009\u00b1\u20090.05\u00a0nM for 3D7 (chloroquine sensitive strain) and DQ IC<jats:sub>50<\/jats:sub> 1.33\u2009\u00b1\u20090.14\u00a0nM for Dd2 (multidrug resistant strain), which were 18- and 14-fold more potent than artemisinin, respectively. Mice did not have any signs of toxicity after receiving high dose of the liposomes (DQ 500\u00a0mg\/kg per mouse) by IV injection. In the mouse model of severe malaria, the liposomes had impressive efficacy against <jats:italic>P. berghei<\/jats:italic> with DQ ED<jats:sub>50<\/jats:sub> of 0.720\u00a0mg\/kg.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The DQ liposomes prepared in this study were stable for long term storage and safe for IV injection in mammalian animals. The newly created liposome formulations had excellent activity against <jats:italic>Plasmodium<\/jats:italic> infection at the blood-stage, which encourages their application in the treatment of severe malaria.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04042-8","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:03:27Z","timestamp":1643022207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Decoquinate liposomes: highly effective clearance of Plasmodium parasites causing severe malaria"],"prefix":"10.1186","volume":"21","author":[{"given":"Sumei","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7583-6190","authenticated-orcid":false,"given":"Hongxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhou","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"4042_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:784\u20136.","journal-title":"N Engl J Med"},{"key":"4042_CR2","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"4042_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin C-S, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral, or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J"},{"key":"4042_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12936-018-2182-z","volume":"17","author":"AP Phyo","year":"2018","unstructured":"Phyo AP, Win KK, Thu AM, Swe LL, Htike H, Beau C, et al. Poor response to artesunate treatment in two patients with severe malaria on the Thai Myanmar border. Malar J. 2018;17:30.","journal-title":"Malar J"},{"key":"4042_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5487\/TR.2013.29.1.027","volume":"29","author":"MK Chung","year":"2013","unstructured":"Chung MK, Yu WJ, Lee JS, Lee JH. Embryotoxicity and toxicokinetics of the antimalarial artesunate in rats. Toxicol Res. 2013;29:27\u201334.","journal-title":"Toxicol Res"},{"key":"4042_CR6","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/S1473-3099(18)30065-3","volume":"18","author":"U D'Alessandro","year":"2018","unstructured":"D\u2019Alessandro U, Hill J, Tarning J, Pell C, Webster J, Gutman J, et al. Treatment of uncomplicated and severe malaria during pregnancy. Lancet Infect Dis. 2018;18:e133\u201346.","journal-title":"Lancet Infect Dis"},{"key":"4042_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2885.2012.01421.x","volume":"35","author":"MA Taylor","year":"2012","unstructured":"Taylor MA, Bartram DJ. The history of decoquinate in the control of coccidial infections in ruminants. J Vet Pharmacol The. 2012;35:417\u201327.","journal-title":"J Vet Pharmacol The"},{"key":"4042_CR8","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.1211936","volume":"334","author":"S Meister","year":"2011","unstructured":"Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SM, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science. 2011;334:1372\u20137.","journal-title":"Science"},{"key":"4042_CR9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1021\/cb200105d","volume":"6","author":"TG Nam","year":"2011","unstructured":"Nam TG, McNamara CW, Bopp S, Dharia NV, Meister S, Bonamy GM, et al. A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem Biol. 2011;6:1214\u201322.","journal-title":"ACS Chem Biol"},{"key":"4042_CR10","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/infdis\/jis184","volume":"205","author":"FP da Cruz","year":"2012","unstructured":"da Cruz FP, Martin C, Buchholz K, Lafuente-Monasterio MJ, Rodrigues T, Sonnichsen B, et al. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis. 2012;205:1278\u201386.","journal-title":"J Infect Dis"},{"key":"4042_CR11","volume":"2013","author":"H Wang","year":"2013","unstructured":"Wang H, Li Q, Reyes S, Zhang J, Xie L, Melendez V, et al. Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity. Malar Res Treat. 2013;2013: 769234.","journal-title":"Malar Res Treat"},{"key":"4042_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.nano.2013.07.010","volume":"10","author":"H Wang","year":"2014","unstructured":"Wang H, Li Q, Reyes S, Zhang J, Zeng Q, Zhang P, et al. Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice. Nanomedicine. 2014;10:57\u201365.","journal-title":"Nanomedicine"},{"key":"4042_CR13","unstructured":"Wang HX, Fan YZ, Chen XQ, Chen XP. A solid dispersion of decoquinate, a preparation process and its application 2019; US Patent: US 10265270 B2."},{"key":"4042_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12936-021-03700-7","volume":"20","author":"NJ White","year":"2021","unstructured":"White NJ. Anti-malarial drug effects on parasite dynamics in vivax malaria. Malar J. 2021;20:161.","journal-title":"Malar J"},{"key":"4042_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/IJN.S68861","volume":"10","author":"G Bozzuto","year":"2015","unstructured":"Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975\u201399.","journal-title":"Int J Nanomed"},{"key":"4042_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1128\/AAC.39.1.180","volume":"39","author":"M Owais","year":"1995","unstructured":"Owais M, Varshney GC, Choudhury A, Chandra S, Gupta CM. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice. Antimicrob Agents Chemother. 1995;39:180\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"4042_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/08982104.2010.539185","volume":"21","author":"B Isacchi","year":"2011","unstructured":"Isacchi B, Arrigucci S, la Marca G, Bergonzi MC, Vannucchi MG, Novelli A, et al. Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. J Liposome Res. 2011;21:237\u201344.","journal-title":"J Liposome Res"},{"key":"4042_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0731-7085(02)00678-7","volume":"31","author":"M Gabri\u00ebls","year":"2003","unstructured":"Gabri\u00ebls M. Physical and chemical evaluation of liposomes, containing artesunate. J Pharm Biomed Anal. 2003;31:655\u201367.","journal-title":"J Pharm Biomed Anal"},{"key":"4042_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajps.2014.06.001","volume":"9","author":"Z Huang","year":"2014","unstructured":"Huang Z, Li X, Zhang T, Song Y, She Z, Li J, et al. Progress involving new techniques for liposome preparation. Asian J Pharm Sci. 2014;9:176\u201382.","journal-title":"Asian J Pharm Sci"},{"key":"4042_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/0005-2736(73)90408-2","volume":"298","author":"S Batzri","year":"1973","unstructured":"Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298:1015\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"4042_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3109\/08982100903347923","volume":"20","author":"C Jaafar-Maalej","year":"2010","unstructured":"Jaafar-Maalej C, Diab R, Andrieu V, Elaissari A, Fessi H. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res. 2010;20:228\u201343.","journal-title":"J Liposome Res"},{"key":"4042_CR22","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.21769\/BioProtoc.2433","volume":"7","author":"JR Jimah","year":"2017","unstructured":"Jimah JR, Schlesinger PH, Tolia NH. Liposome disruption assay to examine lytic properties of biomolecules. Bio Protoc. 2017;7:2433.","journal-title":"Bio Protoc"},{"key":"4042_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.colsurfb.2016.05.037","volume":"145","author":"MR Vijayakumar","year":"2016","unstructured":"Vijayakumar MR, Vajanthri KY, Balavigneswaran CK, Mahto SK, Mishra N, Muthu MS, et al. Pharmacokinetics, biodistribution, in vitro cytotoxicity and biocompatibility of vitamin E TPGS coated trans resveratrol liposomes. Colloids Surf B Biointerfaces. 2016;145:479\u201391.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4042_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1126\/science.781840","volume":"193","author":"W Trager","year":"1976","unstructured":"Trager W, Jensen J. Human malaria parasites in continuous culture. Science. 1976;193:673\u20135.","journal-title":"Science"},{"key":"4042_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2307\/3280287","volume":"65","author":"C Lambros","year":"1979","unstructured":"Lambros C, Vanderberg J. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979;65:418\u201320.","journal-title":"J Parasitol"},{"issue":"Suppl 1","key":"4042_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12936-015-0997-4","volume":"13","author":"MF Dolabela","year":"2015","unstructured":"Dolabela MF, Povoa MM, Brandao GC, Rocha FD, Soares LF, de Paula RC, et al. Aspidosperma species as sources of anti-malarials: uleine is the major anti-malarial indole alkaloid from Aspidosperma parvifolium (Apocynaceae). Malar J. 2015;13(Suppl 1):498.","journal-title":"Malar J"},{"key":"4042_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1128\/AAC.48.5.1803-1806.2004","volume":"48","author":"M Smilkstein","year":"2004","unstructured":"Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother. 2004;48:1803\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"4042_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/00034983.1975.11686997","volume":"69","author":"W Peters","year":"1975","unstructured":"Peters W, Portus J, Robinson B. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann Trop Med Parasitol. 1975;69:155\u201371.","journal-title":"Ann Trop Med Parasitol"},{"key":"4042_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12936-017-1677-3","volume":"16","author":"A Nardos","year":"2017","unstructured":"Nardos A, Makonnen E. In vivo antiplasmodial activity and toxicological assessment of hydroethanolic crude extract of Ajuga remota. Malar J. 2017;16:25.","journal-title":"Malar J"},{"key":"4042_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12936-020-03552-7","volume":"20","author":"Y Alebachew","year":"2021","unstructured":"Alebachew Y, Bisrat D, Tadesse S, Asres K. In vivo anti-malarial activity of the hydroalcoholic extract of rhizomes of Kniphofia foliosa and its constituents. Malar J. 2021;20:3.","journal-title":"Malar J"},{"key":"4042_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1475-2875-10-23","volume":"10","author":"J Langhorne","year":"2011","unstructured":"Langhorne J, Buffet P, Galinski M, Good M, Harty J, Leroy D, et al. The relevance of non-human primate and rodent malaria models for humans. Malar J. 2011;10:23.","journal-title":"Malar J"},{"key":"4042_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"M Danaei","year":"2018","unstructured":"Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10:57.","journal-title":"Pharmaceutics"},{"key":"4042_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119555","volume":"586","author":"D Patel","year":"2020","unstructured":"Patel D, Zode SS, Bansal AK. Formulation aspects of intravenous nanosuspensions. Int J Pharm. 2020;586: 119555.","journal-title":"Int J Pharm"},{"key":"4042_CR34","unstructured":"ASTM Standard F756-08. Standard practice for assessment of hemolytic properties of materials. Annual book of ASTM standard. West Conshohocken: ASTM International; 2008."},{"key":"4042_CR35","first-page":"7508291","volume":"2017","author":"Q Li","year":"2017","unstructured":"Li Q, Xie L, Caridha D, Zeng Q, Zhang J, Roncal N, et al. Long-term prophylaxis and pharmacokinetic evaluation of intramuscular nano- and microparticle decoquinate in mice infected with P. berghei sporozoites. Malar Res Treat. 2017;2017:7508291.","journal-title":"Malar Res Treat"},{"key":"4042_CR36","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.coph.2011.07.006","volume":"11","author":"A MacGowan","year":"2011","unstructured":"MacGowan A. Revisiting beta-lactams\u2014PK\/PD improves dosing of old antibiotics. Curr Opin Pharmacol. 2011;11:470\u20136.","journal-title":"Curr Opin Pharmacol"},{"key":"4042_CR37","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1128\/AAC.00287-13","volume":"57","author":"NJ White","year":"2013","unstructured":"White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother. 2013;57:5792\u2013807.","journal-title":"Antimicrob Agents Chemother"},{"key":"4042_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s42004-018-0062-7","volume":"1","author":"RM Beteck","year":"2018","unstructured":"Beteck RM, Seldon R, Coertzen D, van der Watt ME, Reader J, Mackenzie JS, et al. Accessible and distinct decoquinate derivatives active against Mycobacterium tuberculosis and apicomplexan parasites. Commun Chem. 2018;1:62.","journal-title":"Commun Chem"},{"key":"4042_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetpar.2020.109186","volume":"283","author":"R Bo","year":"2020","unstructured":"Bo R, Dai X, Huang J, Wei S, Liu M, Li J. Evaluation of optimum conditions for decoquinate nanoliposomes and their anticoccidial efficacy against diclazuril-resistant Eimeria tenella infections in broilers. Vet Parasitol. 2020;283: 109186.","journal-title":"Vet Parasitol"},{"key":"4042_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajps.2014.09.004","volume":"10","author":"J Li","year":"2015","unstructured":"Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10:81\u201398.","journal-title":"Asian J Pharm Sci"},{"key":"4042_CR41","volume-title":"Application of nanotechnology in drug delivery","author":"M \u00c7a\u011fda\u015f","year":"2014","unstructured":"\u00c7a\u011fda\u015f M, Sezer AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. In: Sezer AD, editor. Application of nanotechnology in drug delivery. London: Intech Open Publ; 2014."},{"key":"4042_CR42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/10717540601098799","volume":"14","author":"T Yang","year":"2007","unstructured":"Yang T, Cui FD, Choi MK, Lin H, Chung SJ, Shim CK, et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv. 2007;14:301\u20138.","journal-title":"Drug Deliv"},{"key":"4042_CR43","first-page":"178","volume":"145","author":"SD Li","year":"2010","unstructured":"Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Liposome Res. 2010;145:178\u201381.","journal-title":"J Liposome Res"},{"key":"4042_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","volume":"32","author":"GT Noble","year":"2014","unstructured":"Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32:32\u201345.","journal-title":"Trends Biotechnol"},{"key":"4042_CR45","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.2217\/nnm-2019-0243","volume":"14","author":"K Giusto","year":"2019","unstructured":"Giusto K, Patki M, Koya J, Ashby CR, Munnangi S, Patel K, et al. A vaginal nanoformulation of a SphK inhibitor attenuates lipopolysaccharide-induced preterm birth in mice. Nanomedicine. 2019;14:2835\u201351.","journal-title":"Nanomedicine"},{"key":"4042_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0005-2736(86)90411-6","volume":"861","author":"LM Crowe","year":"1986","unstructured":"Crowe LM, Womersley C, Crowe JH, Reid D, Appel L, Rudolph A. Prevention of fusion and leakage in freeze\u2013dried liposomes by carbohydrates. Biochim Biophys Acta. 1986;861:131\u201340.","journal-title":"Biochim Biophys Acta"},{"key":"4042_CR47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/08982104.2014.992023","volume":"25","author":"V Kannan","year":"2015","unstructured":"Kannan V, Balabathula P, Thoma LA, Wood GC. Effect of sucrose as a lyoprotectant on the integrity of paclitaxel-loaded liposomes during lyophilization. J Liposome Res. 2015;25:270\u20138.","journal-title":"J Liposome Res"},{"key":"4042_CR48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ijpharm.2019.03.031","volume":"562","author":"M Ismail","year":"2019","unstructured":"Ismail M, Du Y, Ling L, Li X. Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria. Int J Pharm. 2019;562:162\u201371.","journal-title":"Int J Pharm"},{"key":"4042_CR49","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2147\/IJN.S190692","volume":"14","author":"K Rahman","year":"2019","unstructured":"Rahman K, Khan SU, Fahad S, Chang MX, Abbas A, Khan WU, et al. Nano biotechnology: a new approach to treat and prevent malaria. Int J Nanomed. 2019;14:1401\u201310.","journal-title":"Int J Nanomed"},{"key":"4042_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5694\/j.1326-5377.2005.tb06650.x","volume":"182","author":"TM Davis","year":"2005","unstructured":"Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust. 2005;182:181\u20135.","journal-title":"Med J Aust"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04042-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04042-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04042-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:03:41Z","timestamp":1667779421000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04042-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4042"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04042-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"19 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal study procedures were reviewed and approved by the Institutional Review Committee. Mice were managed in accordance with the Guide for the Care and Use of Laboratory Animals [the Chinese State Council\u2019s Laboratory Animal Management Regulations (Revised March 1, 2017)].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}